{"nctId":"NCT01482910","briefTitle":"VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)","startDateStruct":{"date":"2011-12"},"conditions":["Macular Degeneration"],"count":304,"armGroups":[{"label":"Aflibercept injection (EYLEA, VEGF Trap-Eye, BAY86-5321)","type":"EXPERIMENTAL","interventionNames":["Biological: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)"]},{"label":"PDT treatments","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Visudyne"]}],"interventions":[{"name":"Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","otherNames":[]},{"name":"Visudyne","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed and dated informed consent form\n* Men and women â‰¥ 50 years of age.\n* Active predominantly classic subfoveal choroidal neovascularization (CNV) lesions secondary to wAMD (wet Age-Related Macular Degeneration)\n* BCVA (best corrected visual acuity) of 20/40 to 20/320 in the study eye\n\nExclusion Criteria:\n\n* Only one functional eye\n* Presence of CNV with an origin other than wAMD\n* Any prior ocular or systemic treatment or surgery for wAMD, except dietary supplements or vitamins","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 28 - Last Observation Carried Forward (LOCF)","description":"Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":"12.1"},{"groupId":"OG001","value":"3.9","spread":"14.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Lost Fewer Than 15 Letters at Week 28 - LOCF","description":"Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"92.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":228},"commonTop":["Macular fibrosis","Visual acuity reduced","Conjunctival haemorrhage","Retinal pigment epitheliopathy","Upper respiratory tract infection"]}}}